These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. Schanzer JM; Fichtner I; Baeuerle PA; Kufer P J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804 [TBL] [Abstract][Full Text] [Related]
5. Use of human recombinant antibodies to the marker of angiogenesis ed-b in cancer therapy. Borsi L; Carnemolla B; Neri D; Zardi L Tumori; 2001; 87(6):S8-10. PubMed ID: 11989617 [No Abstract] [Full Text] [Related]
6. Improving the efficacy of antibody-based cancer therapies. Carter P Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803 [TBL] [Abstract][Full Text] [Related]
7. The use of phage display for the development of tumour targeting agents. Nilsson F; Tarli L; Viti F; Neri D Adv Drug Deliv Rev; 2000 Sep; 43(2-3):165-96. PubMed ID: 10967225 [TBL] [Abstract][Full Text] [Related]
8. Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins. Lode HN; Xiang R; Gillies SD; Reisfeld RA Immunol Invest; 2000 May; 29(2):117-20. PubMed ID: 10854178 [No Abstract] [Full Text] [Related]
9. Targeted delivery of tissue factor to tumor neovasculature for cancer therapy. Neri D Haemostasis; 2001; 31 Suppl 1():21-2. PubMed ID: 11990467 [No Abstract] [Full Text] [Related]
10. Cancer: one step at a time. Mooney D Nature; 2005 Jul; 436(7050):468-9. PubMed ID: 16049458 [No Abstract] [Full Text] [Related]
11. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate. Pasche N; Frey K; Neri D Angiogenesis; 2012 Mar; 15(1):165-9. PubMed ID: 22052195 [TBL] [Abstract][Full Text] [Related]
12. In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer. Xie H; Blättler WA Expert Opin Biol Ther; 2006 Mar; 6(3):281-91. PubMed ID: 16503736 [TBL] [Abstract][Full Text] [Related]
14. Regression of CD30+ cutaneous anaplastic large-cell lymphoma with denileukin diftitox. Dao H; Barr PM; Honda K J Am Acad Dermatol; 2011 Jun; 64(6):e123-5. PubMed ID: 21571160 [No Abstract] [Full Text] [Related]
15. Toward a systems engineering approach to cancer drug delivery. Dreher MR; Chilkoti A J Natl Cancer Inst; 2007 Jul; 99(13):983-5. PubMed ID: 17596569 [No Abstract] [Full Text] [Related]
16. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells. Schanzer JM; Baeuerle PA; Dreier T; Kufer P Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188 [TBL] [Abstract][Full Text] [Related]
17. Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy. Stylianopoulos T; Munn LL; Jain RK Trends Cancer; 2018 Apr; 4(4):258-259. PubMed ID: 29606306 [TBL] [Abstract][Full Text] [Related]
18. In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. Seo BR; DelNero P; Fischbach C Adv Drug Deliv Rev; 2014 Apr; 69-70():205-216. PubMed ID: 24309015 [TBL] [Abstract][Full Text] [Related]
19. The critical role of vascular endothelial growth factor in tumor angiogenesis. Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH Curr Cancer Drug Targets; 2012 Jan; 12(1):23-43. PubMed ID: 22111836 [TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of tumor endothelial cells and drug delivery. Hida K; Maishi N; Sakurai Y; Hida Y; Harashima H Adv Drug Deliv Rev; 2016 Apr; 99(Pt B):140-147. PubMed ID: 26626622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]